Winfred Woodrow Williams, Jr., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 32 | 2022 | 4246 | 1.310 |
Why?
|
| Organ Preservation | 2 | 2023 | 324 | 0.900 |
Why?
|
| Cold Ischemia | 1 | 2023 | 65 | 0.870 |
Why?
|
| Kidney Failure, Chronic | 9 | 2020 | 2536 | 0.720 |
Why?
|
| Organ Transplantation | 3 | 2023 | 1135 | 0.630 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2022 | 485 | 0.600 |
Why?
|
| Medicine | 2 | 2023 | 941 | 0.570 |
Why?
|
| Kidney | 21 | 2021 | 7167 | 0.550 |
Why?
|
| Hepatitis C, Chronic | 3 | 2021 | 1027 | 0.540 |
Why?
|
| Kidney Diseases | 5 | 2023 | 2145 | 0.540 |
Why?
|
| Antiviral Agents | 7 | 2021 | 2978 | 0.480 |
Why?
|
| Health Status Disparities | 2 | 2021 | 1794 | 0.440 |
Why?
|
| Liver Transplantation | 5 | 2021 | 2117 | 0.430 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 2043 | 0.420 |
Why?
|
| Hepatitis C | 9 | 2021 | 1582 | 0.410 |
Why?
|
| Apolipoproteins | 1 | 2013 | 315 | 0.400 |
Why?
|
| Diabetic Nephropathies | 3 | 2013 | 983 | 0.390 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3151 | 0.390 |
Why?
|
| Lipoproteins, HDL | 1 | 2013 | 637 | 0.340 |
Why?
|
| Students, Medical | 1 | 2021 | 1858 | 0.310 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 1640 | 0.290 |
Why?
|
| Complement C4b | 6 | 2002 | 135 | 0.270 |
Why?
|
| Cyclosporine | 5 | 2004 | 784 | 0.270 |
Why?
|
| Immunosuppressive Agents | 13 | 2009 | 4147 | 0.250 |
Why?
|
| Hepacivirus | 4 | 2021 | 1372 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2013 | 3336 | 0.230 |
Why?
|
| Journalism, Medical | 1 | 2023 | 74 | 0.220 |
Why?
|
| Graft Survival | 3 | 2012 | 3733 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 2195 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 552 | 0.210 |
Why?
|
| Lupus Nephritis | 1 | 2005 | 310 | 0.210 |
Why?
|
| Graft Rejection | 13 | 2012 | 4393 | 0.200 |
Why?
|
| Aminoisobutyric Acids | 1 | 2020 | 38 | 0.190 |
Why?
|
| School Admission Criteria | 1 | 2021 | 105 | 0.180 |
Why?
|
| Ribavirin | 3 | 2015 | 395 | 0.180 |
Why?
|
| Cold Temperature | 1 | 2023 | 774 | 0.170 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 340 | 0.170 |
Why?
|
| Social Justice | 1 | 2023 | 455 | 0.170 |
Why?
|
| Cyclopropanes | 1 | 2020 | 416 | 0.170 |
Why?
|
| Leucine | 1 | 2020 | 560 | 0.170 |
Why?
|
| Lactams, Macrocyclic | 1 | 2020 | 319 | 0.160 |
Why?
|
| Proline | 1 | 2020 | 458 | 0.160 |
Why?
|
| Quinoxalines | 1 | 2020 | 288 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2023 | 791 | 0.160 |
Why?
|
| Tacrolimus | 4 | 2004 | 741 | 0.160 |
Why?
|
| Interferon-alpha | 3 | 2015 | 895 | 0.150 |
Why?
|
| Humans | 57 | 2023 | 742088 | 0.150 |
Why?
|
| Cryoglobulinemia | 2 | 2015 | 87 | 0.140 |
Why?
|
| Nephrology | 1 | 2020 | 260 | 0.140 |
Why?
|
| Perfusion | 1 | 2021 | 1359 | 0.140 |
Why?
|
| Pre-Eclampsia | 1 | 2005 | 1196 | 0.140 |
Why?
|
| Complement C4 | 6 | 2002 | 257 | 0.130 |
Why?
|
| Mycophenolic Acid | 4 | 2003 | 343 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2020 | 848 | 0.130 |
Why?
|
| Complement Activation | 4 | 2001 | 452 | 0.130 |
Why?
|
| Elastic Modulus | 1 | 2015 | 213 | 0.120 |
Why?
|
| Schools, Medical | 1 | 2021 | 878 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1155 | 0.120 |
Why?
|
| Minority Groups | 1 | 2021 | 1215 | 0.110 |
Why?
|
| Outpatients | 1 | 2020 | 1483 | 0.110 |
Why?
|
| RNA, Viral | 2 | 2020 | 2899 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2013 | 326 | 0.110 |
Why?
|
| Ireland | 1 | 2012 | 160 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 2861 | 0.100 |
Why?
|
| Erythropoietin | 2 | 2012 | 724 | 0.100 |
Why?
|
| Finland | 1 | 2012 | 602 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2020 | 1932 | 0.100 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 742 | 0.090 |
Why?
|
| Isoantibodies | 4 | 2009 | 680 | 0.090 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 4771 | 0.090 |
Why?
|
| Transplantation Tolerance | 2 | 2008 | 617 | 0.090 |
Why?
|
| Tissue Donors | 5 | 2021 | 2205 | 0.090 |
Why?
|
| Education, Medical | 1 | 2021 | 1717 | 0.090 |
Why?
|
| Peptide Fragments | 6 | 2002 | 5095 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 430 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2275 | 0.080 |
Why?
|
| Nephrotic Syndrome | 2 | 2005 | 389 | 0.080 |
Why?
|
| Glomerulonephritis | 2 | 2002 | 372 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 17400 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1820 | 0.070 |
Why?
|
| Pregnancy | 3 | 2022 | 29087 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 1999 | 1155 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1780 | 0.070 |
Why?
|
| Antibodies | 4 | 2022 | 2459 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2021 | 6540 | 0.070 |
Why?
|
| United States | 5 | 2021 | 69693 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2021 | 3306 | 0.070 |
Why?
|
| Clinical Chemistry Tests | 1 | 2005 | 61 | 0.070 |
Why?
|
| Adult | 27 | 2020 | 213712 | 0.060 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 612 | 0.060 |
Why?
|
| Pregnancy Proteins | 1 | 2005 | 229 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 1988 | 969 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2003 | 29 | 0.060 |
Why?
|
| Ethics, Professional | 1 | 2023 | 102 | 0.060 |
Why?
|
| Female | 27 | 2022 | 379592 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 1470 | 0.060 |
Why?
|
| Scientific Misconduct | 1 | 2023 | 71 | 0.060 |
Why?
|
| Thymus Gland | 1 | 1988 | 1264 | 0.050 |
Why?
|
| Complement C3b | 2 | 1999 | 106 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 1988 | 2723 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2015 | 21719 | 0.050 |
Why?
|
| Menstruation | 1 | 2003 | 299 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2003 | 491 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2915 | 0.050 |
Why?
|
| Contraception Behavior | 1 | 2003 | 184 | 0.050 |
Why?
|
| Male | 31 | 2020 | 349538 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2023 | 720 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5425 | 0.050 |
Why?
|
| HLA Antigens | 3 | 2001 | 1382 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 5851 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 5867 | 0.050 |
Why?
|
| Postoperative Complications | 5 | 2019 | 15244 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 2167 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2011 | 2723 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 802 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 2763 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 766 | 0.040 |
Why?
|
| Kidney Tubules | 3 | 2012 | 486 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2013 | 12220 | 0.040 |
Why?
|
| Premenopause | 1 | 2003 | 1033 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 62 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2001 | 246 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 1999 | 96 | 0.040 |
Why?
|
| Antibody Formation | 5 | 2002 | 1402 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1999 | 112 | 0.040 |
Why?
|
| Ischemia | 3 | 1996 | 1911 | 0.040 |
Why?
|
| Biopsy | 5 | 2008 | 6756 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2020 | 342 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1998 | 155 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2001 | 795 | 0.040 |
Why?
|
| Cardiolipins | 1 | 1997 | 88 | 0.040 |
Why?
|
| Middle Aged | 24 | 2019 | 213127 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2019 | 1597 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2023 | 1533 | 0.040 |
Why?
|
| Donor Selection | 1 | 2019 | 201 | 0.040 |
Why?
|
| Phenanthridines | 1 | 1996 | 51 | 0.040 |
Why?
|
| Fibrosis | 2 | 2015 | 2026 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2003 | 1484 | 0.040 |
Why?
|
| Platelet Activating Factor | 1 | 1996 | 149 | 0.040 |
Why?
|
| Renal Artery | 1 | 1999 | 398 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 1997 | 242 | 0.040 |
Why?
|
| Placenta | 1 | 2005 | 1694 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 4455 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2020 | 692 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1996 | 333 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2023 | 2739 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 1998 | 697 | 0.030 |
Why?
|
| Acute Disease | 6 | 2003 | 7141 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2020 | 1961 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1998 | 359 | 0.030 |
Why?
|
| Triazines | 1 | 1996 | 316 | 0.030 |
Why?
|
| Phenotype | 1 | 2012 | 16331 | 0.030 |
Why?
|
| Viremia | 1 | 1997 | 735 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8297 | 0.030 |
Why?
|
| Sp3 Transcription Factor | 1 | 2013 | 29 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 932 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15530 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 19862 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 657 | 0.030 |
Why?
|
| Peroxidase | 4 | 1999 | 610 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 10163 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 2099 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 12958 | 0.030 |
Why?
|
| Informed Consent | 1 | 2019 | 991 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 1538 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2001 | 4664 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 29010 | 0.020 |
Why?
|
| Maleimides | 1 | 2011 | 112 | 0.020 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2015 | 388 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 6608 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 6483 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 1999 | 1155 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1237 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1998 | 4554 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2021 | 77098 | 0.020 |
Why?
|
| Acute Kidney Injury | 3 | 1999 | 1967 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 644 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2009 | 178 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4197 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2020 | 53187 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 1 | 1988 | 112 | 0.020 |
Why?
|
| Chronic Disease | 5 | 2003 | 9144 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1999 | 1348 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2001 | 3119 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 902 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 1599 | 0.020 |
Why?
|
| Aged | 7 | 2019 | 162944 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2011 | 1146 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3439 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 170 | 0.020 |
Why?
|
| Creatinine | 3 | 1999 | 1916 | 0.020 |
Why?
|
| Serine | 1 | 2011 | 828 | 0.020 |
Why?
|
| Capillaries | 2 | 2001 | 774 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2011 | 1802 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 270 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 712 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1343 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 1058 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2002 | 2505 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2008 | 547 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2005 | 25575 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2011 | 1538 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 1284 | 0.020 |
Why?
|
| Anemia | 1 | 1994 | 1499 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2001 | 4566 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2015 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2011 | 1887 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 2001 | 1606 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5724 | 0.010 |
Why?
|
| Thrombosis | 1 | 1997 | 2966 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2008 | 13029 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2013 | 2585 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 2 | 2001 | 2699 | 0.010 |
Why?
|
| Indoles | 1 | 2011 | 1834 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1988 | 986 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 6382 | 0.010 |
Why?
|
| Complement C5b | 1 | 2001 | 9 | 0.010 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 2001 | 12 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 3862 | 0.010 |
Why?
|
| Spleen | 1 | 1988 | 2359 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1999 | 8300 | 0.010 |
Why?
|
| Complement C5 | 1 | 2001 | 111 | 0.010 |
Why?
|
| Rats | 4 | 1999 | 24265 | 0.010 |
Why?
|
| Family Planning Services | 1 | 2003 | 258 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 894 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 3 | 1999 | 9274 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 8436 | 0.010 |
Why?
|
| Natriuresis | 1 | 1999 | 124 | 0.010 |
Why?
|
| Animals | 8 | 2011 | 168561 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 4414 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 1333 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 12730 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2001 | 1094 | 0.010 |
Why?
|
| Inflammation | 1 | 1999 | 10578 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 112 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1185 | 0.010 |
Why?
|
| Incidence | 3 | 2003 | 20928 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1998 | 317 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 9735 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 110 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 15108 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5975 | 0.010 |
Why?
|
| Mice | 4 | 2011 | 81045 | 0.010 |
Why?
|
| Time Factors | 4 | 2003 | 40054 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1999 | 388 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2384 | 0.010 |
Why?
|
| Immunization | 1 | 2001 | 1255 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1581 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1988 | 5519 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1999 | 626 | 0.010 |
Why?
|
| Growth Substances | 1 | 1998 | 783 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2001 | 1839 | 0.010 |
Why?
|
| Steroids | 1 | 2001 | 931 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8621 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 327 | 0.010 |
Why?
|
| Reperfusion | 1 | 1996 | 284 | 0.010 |
Why?
|
| Iothalamic Acid | 1 | 1994 | 18 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 2895 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 1608 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 5522 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 2354 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 2645 | 0.010 |
Why?
|
| Proteinuria | 1 | 1997 | 657 | 0.010 |
Why?
|
| Models, Biological | 1 | 2011 | 9581 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 24913 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1285 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1849 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11470 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 1637 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 1827 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 21821 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 15494 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 56350 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1994 | 378 | 0.010 |
Why?
|
| Azathioprine | 1 | 1994 | 355 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 4982 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1999 | 8541 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 1030 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 3571 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 1517 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 2006 | 0.010 |
Why?
|
| Length of Stay | 1 | 2003 | 6294 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 9305 | 0.010 |
Why?
|
| Prednisone | 1 | 1994 | 1567 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1996 | 3913 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1994 | 2372 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2011 | 23387 | 0.000 |
Why?
|
| Reoperation | 1 | 1997 | 4200 | 0.000 |
Why?
|
| Heart Rate | 1 | 1999 | 4091 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7790 | 0.000 |
Why?
|
| Risk Factors | 2 | 2004 | 72145 | 0.000 |
Why?
|
| Cell Line | 1 | 1998 | 15994 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 10943 | 0.000 |
Why?
|
| Neutrophils | 1 | 1996 | 3711 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 1996 | 14554 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 35070 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2001 | 40955 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2001 | 40450 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 62966 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 13655 | 0.000 |
Why?
|
| Child | 1 | 2001 | 77478 | 0.000 |
Why?
|